Pfizer to price COVID-19 vaccine below 'typical market rates': BioNTech
- 3 years ago
'화이자 백신' 공동 개발사 "시세보다 낮게 가격 책정할 것"
Our top story this morning.
BioNTech,... the German biotech firm working with Pfizer to develop a COVID-19 vaccine,... says it plans to price the two-dose vaccine below "typical market rates",... and will set different prices depending on countries or regions.
Speaking to the Financial Times on Tuesday,... a senior BioNTech representative said the price will reflect the current situation,... with the goal to ensure broad-based access globally.
The vaccine has been shown to be more than 90-percent effective,... based on its preliminary trial results.
The companies hope to supply 1-point-3 billion doses by 2021.
Our top story this morning.
BioNTech,... the German biotech firm working with Pfizer to develop a COVID-19 vaccine,... says it plans to price the two-dose vaccine below "typical market rates",... and will set different prices depending on countries or regions.
Speaking to the Financial Times on Tuesday,... a senior BioNTech representative said the price will reflect the current situation,... with the goal to ensure broad-based access globally.
The vaccine has been shown to be more than 90-percent effective,... based on its preliminary trial results.
The companies hope to supply 1-point-3 billion doses by 2021.